RSS

Lundbeck

Lundbeck has signed a definitive agreement to acquire biopharma company, Prexton Therapeutics, obtaining the global rights for foliglurax — a treatment for Parkinson’s that has recently entered clinical Phase II testing. more

News

A drug that was believed to be a promising new therapeutic option for suffers of Alzheimer’s (idalopirdine) — from the Danish pharma company, Lundbeck — has failed to show clinical benefit in three randomised trials. more

News